Harrow Health (HROW) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Harrow Health (HROW) Misses Q1 EPS by 8c
May 13, 2024 4:01 PM EDT
First Quarter 2024 and Recent Selected Highlights:
Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter.
Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable for unilateral and bilateral in-office procedures, retroactive to January 1, 2024.
Recently signed IHEEZO supply agreements with seven multi-practice strategic accounts.
U.S. Patent and Trademark Office recently granted new IHEEZO patent claims with an expiry through 2039.
Sequential month-over-month growth in VEVYE total prescriptions, new prescriptions, prescribers, and refills.
Covered lives for VEVYE increased to 150+...
More
